Diagnosis Restricted Drugs

The table below includes a list of drugs that are diagnosis-restricted for pharmacy compound and non-compound claims. This table specifies if the diagnosis must be indicated on the claim, prior authorization (PA) request, or both. See the link below for physician-administered diagnosis restrictions.

If the prescriber writes a prescription with a diagnosis outside the ForwardHealth-allowed diagnoses for a drug, the prescriber is required to submit peer-reviewed medical literature to support the proven efficacy and safety of the requested use of the drug. Documentation of previous treatments and detailed reasons why other covered drug treatments were discontinued or not utilized are required. Medical records should be provided as necessary to support the PA request. This information should be documented on the Prior Authorization/Drug Attachment (PA/DGA), F- 11049 (10/13), in Section V (Clinical Information for Diagnosis-Restricted Drug Requests).

When completing the PA/DGA, prescribers should provide the diagnosis code and description, complete Section V, and use Section VIII (Additional Information), if needed. Prescribers are reminded to provide a handwritten signature and date on the form before submitting it to the pharmacy provider where the prescription will be filled. The pharmacy provider is required to complete a Prior Authorization Request Form (PA/RF), F- 11018 (05/13), before submitting the forms and supporting documentation to ForwardHealth. Prescribers should not submit PA forms to ForwardHealth.

As a reminder, prescribers and pharmacy providers are required to retain a completed copy of the PA form(s).

For additional information about diagnosis-restricted drug policy, providers may refer to the ForwardHealth Online Handbook Topic #4403, 15537, and 15937:

https://www.forwardhealth.wi.gov/wiportal/subsystem/kw/display.aspx

Physician Administered diagnosis restrictions can be found at:

https://www.forwardhealth.wi.gov/WIPortal/Tab/42/icscontent/Provider/medicaid/physician/data_tables/index.htm.spage

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Alzheimer's Agents

| AMENDA XR (| memantine hcl) | | |
|-------------|---|--|--|
| Diagnos | is Code Must Be Submitted on: Claim ✓ Prior Authorization Request ✓ | | |
| ICD-10 | Description | | |
| F0150 | /ascular dementia without behavioral disturbance | | |
| F0151 | ascular denentia with behavioral disturbance | | |
| G300 | Alzheimer's disease with early onset | | |
| G301 | Alzheimer's disease with late onset | | |
| G308 | Other alzheimer's disease | | |
| G309 | Alzheimer's disease, unspecified | | |

Antibiotics, Inhaled

| _ | | 4 . |
|---|-----|-------|
| r | ron | lucts |
| | | |

ARIKAYCE (amikacin liposomal)

| Diagnos | is Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request |
|---------|-----------------------------------|------------------|-----------------------------|
| ICD-10 | Description | | |
| A310 | Pulmonary mycobacterial infection | | |
| A312 | Disseminated mycobacterium aviur | m-intracellulare | complex (DMAC) |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Anticonvulsants

SYMPAZAN (clobazam)

| Produ | cts | |
|--------|---------------|--|
| DIACC | OMIT (stiripe | entol) |
| | Diagnosis | s Code Must Be Submitted on: Claim 🗸 Prior Authorization Request 🗸 |
| | ICD-10 | Description |
| | G40833 | Dravet Syndrome, Intractable, with status Epilepticus |
| | G40834 | Dravet Syndrome, Intractable, without status Epilepticus |
| Produ | cts | |
| EPIDIO | OLEX (canr | nabidiol) |
| | (| |
| | Diagnosis | s Code Must Be Submitted on: Claim Prior Authorization Request |
| | ICD-10 | Description |
| | G40811 | Lennox-Gastaut syndrome, not intractable, with status epilepticus |
| | G40812 | Lennox-Gastaut syndrome, not intractable, without status epilepticus |
| | G40813 | Lennox-Gastaut syndrome, intractable, with status epilepticus |
| | G40814 | Lennox-Gastaut syndrome, intractable, without status epilepticus |
| | G40833 | Dravet Syndrome, Intractable, with status Epilepticus |
| | G40834 | Dravet Syndrome, Intractable, without status Epilepticus |
| | Q851 | Tuberous Sclerosis |
| BANZE | • | s Code Must Be Submitted on: Claim 🕡 Prior Authorization Request 🗸 |
| | ICD-10 | Description |
| | G40811 | Lennox-Gastaut syndrome, not intractable, with status epilepticus |
| | G40812 | Lennox-Gastaut syndrome, not intractable, without status epilepticus |
| | G40813 | Lennox-Gastaut syndrome, intractable, with status epilepticus |
| | G40814 | Lennox-Gastaut syndrome, intractable, without status epilepticus |
| Produ | cts | |
| FINTE | PLA (fenflu | uramine) |
| | Diagnosis | s Code Must Be Submitted on: Claim 👽 Prior Authorization Request 👽 |
| | ICD-10 | Description |
| | G40811 | Lennox-Gastaut syndrome, not intractable, with status epilepticus |
| | G40812 | Lennox-Gastaut syndrome, not intractable, without status epilepticus |
| | G40813 | Lennox-Gastaut syndrome, intractable, with status epilepticus |
| | G40814 | Lennox-Gastaut syndrome, intractable, without status epilepticus |
| | G40833 | Dravet Syndrome, Intractable, with status Epilepticus |
| | G40834 | Dravet Syndrome, Intractable, without status Epilepticus |
| Produ | cts | • |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Anticonvulsants Claim 🗸 Diagnosis Code Must Be Submitted on: Prior Authorization Request ICD-10 Description G40811 Lennox-Gastaut syndrome, not intractable, with status epilepticus G40812 Lennox-Gastaut syndrome, not intractable, without status epilepticus G40813 Lennox-Gastaut syndrome, intractable, with status epilepticus G40814 Lennox-Gastaut syndrome, intractable, without status epilepticus Antineoplastic and Premalignant Lesion Agent, Topical **Products** diclofenac sodium 3% gel (Example brand: SOLARAZE) Diagnosis Code Must Be Submitted on: Claim 🗸 Prior Authorization Request **ICD-10** Description L570 Actinic Keratosis **Antiviral Agents Products** LIVTENCITY (maribavir) Diagnosis Code Must Be Submitted on: Claim 🗸 Prior Authorization Request ICD-10 Description B250 Cytomegaloviral disease pneumonitis B251 Cytomegaloviral disease hepatitis B252 Cytomegaloviral disease pancreatitis

B258

B259

Other cytomegaloviral diseases

Cytomegaloviral disease, Unspecified

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023 Effective: 1/1/2023

Central Nervous System Agents, Miscellaneous

| Products | | | | |
|-------------|---------------------------------------|----------|-------------------------------|---|
| RELYVRIO (I | phenylbutyrate) | | RILUTEK (riluzole) | |
| Diagr | nosis Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | |
| ICD-1 | 0 Description | | | |
| G122 | · · · · · · · · · · · · · · · · · · · | | | |
| Products | - | | | • |
| NUEDEXTA | (dextromethorphan hbr/quinidine) | | | |
| Diagr | nosis Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | |
| ICD-1 | 0 Description | | | |
| F482 | Pseudobulbar affect | | | |
| Products | | | | |
| BRONCHITC | L (mannitol) | | | _ |
| | | | | |
| Diagr | nosis Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | |
| ICD-1 | 0 Description | | | |
| E840 | Cystic Fibrosis with Pulmonary Ma | | | |
| E841 | , | | | |
| E841 | , | | | |
| E848 | | stations | | |
| E849 | Cystic Fibrosis, Unspecified | | | |
| amma A | Aminobutyric Acid Clas | S | | |
| Products | | | | |
| GRALISE (ga | abapentin) | | | _ |
| Diagr | nosis Code Must Be Submitted on: | Claim | Prior Authorization Request 🗸 | |
| ICD-1 | 0 Description | | | |
| B022 | | tis | | |
| B022 | | | | |
| B022 | 3 Postherpetic polyneuropathy | | | |
| D022 | | | | |
| B022 | | | | |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023 Effective: 1/1/2023

Lipdystrophy

| Produ | ıcts | | | | _ |
|---------------|------------|------------------------------------|-----------------|--|---|
| MYAL | EPT (metro | eleptin) | | | |
| | Diagnos | s Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | |
| | ICD-10 | Description | | | |
| | E881 | Lipodystrophy, not elsewhere class | sified | | 1 |
| Produ | ıcts | | | | _ |
| EGRIF | FTA SV (te | samorelin) | | | |
| | Diagnos | s Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | |
| | Both diad | nosis codes required or see below | | | |
| | ICD-10 | Description | | | |
| | B20 | Human immunodeficiency virus [H | IV] Disease | | 7 |
| | E881 | Lipodystrophy, not elsewhere class | | | 1 |
| | Or an alte | ernative combination of codes | | | _ |
| | ICD-10 | Description | | | |
| | B9735 | • | pe 2 [HIV 2] as | the cause of diseases classified elsewhere | 1 |
| | E881 | Lipodystrophy, not elsewhere class | sified | | 1 |
| ipod Produ | OSES | | | | |
| CERD | ELGA (eliç | llustat tartrate) | | ZAVESCA (miglustat) | |
| | Diagnos | s Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | |
| | ICD-10 | Description | | | |
| | E7522 | Gaucher disease | | | 1 |
| ysos | somal | Storage Disorder | | | |
| Produ | ıcts | | | | |
| GALA | FOLD (mig | alastat) | | | |
| | Diagnos | s Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | |
| | ICD-10 | Description | | | |
| | E7521 | Fabry (-Anderson) Disease | | | 1 |
| | | • | | | - |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

| VIO۱ | /em | nent | Disor | ders |
|------|-----|------|-------|------|
| | | | | |
| | | | | |

| ICD-10 | | | |
|---------------|---------------------------------|---------|--|
| | sis Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request |
| | Description | | · |
| G10 | Huntington's Disease | | |
| G2401 | Drug Induced Subacute Dyskinesi | a | |
| G2402 | Other induced Acute Dystonia | | |
| G2409 | Other Drug Induced Dystonia | | |
| Products | | | |
| INGREZZA (va | lbenazine) | | INGREZZA INITIATION PACK (valbenazine) |
| Diagno | sis Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request |
| ICD-10 | Description | | |
| G2401 | Drug Induced Subacute Dyskinesi | a | |
| G2402 | Drug Induced Acute Dystonia | | |
| G2409 | Other Drug Induced Dystonia | | |
| Products | | | |
| XENAZINE (tet | rabenazine) | | |
| Diagno | sis Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request |
| ICD-10 | Description | | |
| G10 | HUNTINGTON'S DISEASE | | |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Neuropathic Pain

| cts | |
|-----------|--|
| A CR (pre | egabalin) |
| Diagnos | sis Code Must Be Submitted on: Claim 🗸 Prior Authorization Request 🗸 |
| ICD-10 | Description |
| B0221 | POSTHERPETIC GENICULATE GANGLIONITIS |
| B0222 | POSTHERPETIC TRIGEMINAL NEURALGIA |
| B0223 | POSTHERPETIC POLYNEUROPATHY |
| B0224 | POSTHERPETIC MYELITIS |
| B0229 | OTHER POSTHERPETIC NERVOUS SYSTEM INVOLVEMENT |
| E1040 | TYPE 1 DIABETES MELLITUS WITH DIABETIC NEUROPATHY, UNSPECIFIED |
| E1041 | TYPE 1 DIABETES MELLITUS WITH DIABETIC MONONEUROPATHY |
| E1042 | TYPE 1 DIABETES MELLITUS WITH DIABETIC POLYNEUROPATHY |
| E1043 | TYPE 1 DIABETES MELLITUS WITH DIABETIC AUTONOMIC (POLY)NEUROPATHY |
| E1044 | TYPE 1 DIABETES MELLITUS WITH DIABETIC AMYOTROPHY |
| E1049 | TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC NEUROLOGICAL COMPLICATION |
| E1140 | TYPE 2 DIABETES MELLITUS WITH DIABETIC NEUROPATHY, UNSPECIFIED |
| E1141 | TYPE 2 DIABETES MELLITUS WITH DIABETIC MONONEUROPATHY |
| E1142 | TYPE 2 DIABETES MELLITUS WITH DIABETIC POLYNEUROPATHY |
| E1143 | TYPE 2 DIABETES MELLITUS WITH DIABETIC AUTONOMIC (POLY)NEUROPATHY |
| E1144 | TYPE 2 DIABETES MELLITUS WITH DIABETIC AMYOTROPHY |
| E1149 | TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC NEUROLOGICAL COMPLICATION |

Ophthalmics, Presbyopia

| Products | | | | |
|------------------|-------------------------------|---------|-----------------------------|--|
| VUITY (pilocarpi | ine) | | | |
| Diagnos | is Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | |
| ICD-10 | Description | | | |
| H524 | Presbyopia | | | |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Opioid Dependency - Buprenorphine

| ouprenorphine | hcl (Example brand: SUBUTEX) | | buprenorphine-naloxone (Example brand: SUBOXON | | |
|---------------|-----------------------------------|---|--|--|--|
| | buprenorphine) | | SUBOXONE (buprenorphine hcl/naloxone) | | |
| ZUBSOLV (bup | orenorphine hcl/naloxone) | | , , , , | | |
| Diagno | sis Code Must Be Submitted on: | Claim 🗸 | Prior Authorization Request | | |
| ICD-10 | Description | | | | |
| F1120 | Opioid dependence, uncomplicated | b | | | |
| F1120 | Opioid dependence, uncomplicated | b | | | |
| F1121 | Opioid dependence, in remission | | | | |
| F1124 | Opioid dependence with opioid-ind | Opioid dependence with opioid-induced mood disorder | | | |
| F11250 | Opioid dependence with opioid-ind | uced psychotic | disorder with delusions | | |
| F11251 | Opioid dependence with opioid-ind | uced psychotic | disorder with hallucinations | | |
| F11259 | Opioid dependence with opioid-ind | uced psychotic | disorder, unspecified | | |
| F11281 | Opioid dependence with opioid-ind | uced sexual dys | sfunction | | |
| F11282 | Opioid dependence with opioid-ind | uced sleep diso | rder | | |
| F11288 | Opioid dependence with other opio | id-induced diso | rder | | |
| F1129 | Opioid dependence with unspecifie | ed opioid-induce | d disorder | | |

Opioid Dependency Agents - Methadone

| KETS 40 MG | G TABLET DISPR (methadone hcl) METHADONE INTENSOL 10 MG/ML (methad | _ one hcl) | | |
|------------|--|--------------------------|--|--|
| | 10 MG/ML ORAL CONC (methadone hcl) METHADOSE 40 MG TABLET DISPR (methadone hcl) | , | | |
| Diagnos | sis Code Must Be Submitted on: Claim 🗹 Prior Authorization Request 🗌 | | | |
| ICD-10 | Description | | | |
| F1120 | Opioid dependence, uncomplicated | 7 | | |
| F1121 | Opioid dependence, in remission | | | |
| F1124 | Opioid dependence with opioid-induced mood disorder | | | |
| F11250 | Opioid dependence with opioid-induced psychotic disorder with delusions | | | |
| F11251 | Opioid dependence with opioid-induced psychotic disorder with hallucinations | | | |
| F11259 | Opioid dependence with opioid-induced psychotic disorder, unspecified | | | |
| F11281 | Opioid dependence with opioid-induced sexual dysfunction | | | |
| F11282 | Opioid dependence with opioid-induced sleep disorder | | | |
| F11288 | Opioid dependence with other opioid-induced disorder | | | |
| F1129 | Opioid dependence with unspecified opioid-induced disorder | | | |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023 Effective: 1/1/2023

Opioid Dependency and Alcohol Abuse/Dependency Agents

| oducts | | | |
|----------------|--|--|--|
| trexone hcl (E | rexone hcl (Example brand: REVIA) VIVITROL (naltrexone microspheres) | | |
| Diagnosi | s Code Must Be Submitted on: Claim 🕡 Prior Authorization Request 🗌 | | |
| ICD-10 | Description | | |
| F1010 | Alcohol abuse, uncomplicated | | |
| F1011 | Alcohol abuse, uncomplicated | | |
| F1014 | Alcohol abuse with alcohol-induced mood disorder | | |
| F10150 | Alcohol abuse with alcohol-induced psychotic disorder with delusions | | |
| F10151 | Alcohol abuse with alcohol-induced psychotic disorder with hallucinations | | |
| F10159 | Alcohol abuse with alcohol-induced psychotic disorder, unspecified | | |
| F10180 | Alcohol abuse with alcohol-induced anxiety disorder | | |
| F10181 | Alcohol abuse with alcohol-induced sexual dysfunction | | |
| F10182 | Alcohol abuse with alcohol-induced sleep disorder | | |
| F10188 | Alcohol abuse with other alcohol-induced disorder | | |
| F1019 | Alcohol abuse with unspecified alcohol-induced disorder | | |
| F1020 | Alcohol dependence, uncomplicated | | |
| F1021 | Alcohol dependence, in remission | | |
| F1024 | Alcohol dependence with alcohol-induced mood disorder | | |
| F10250 | Alcohol dependence with alcohol-induced psychotic disorder with delusions | | |
| F10251 | Alcohol dependence with alcohol-induced psychotic disorder with hallucinations | | |
| F10259 | Alcohol dependence with alcohol-induced psychotic disorder, unspecified | | |
| F1026 | Alcohol dependence with alcohol-induced persisting amnestic disorder | | |
| F1027 | Alcohol dependence with alcohol-induced persisting dementia | | |
| F10280 | Alcohol dependence with alcohol-induced anxiety disorder | | |
| F10281 | Alcohol dependence with alcohol-induced sexual dysfunction | | |
| F10282 | Alcohol dependence with alcohol-induced sleep disorder | | |
| F10288 | Alcohol dependence with other alcohol-induced disorder | | |
| F1029 | Alcohol dependence with unspecified alcohol-induced disorder | | |
| F1094 | Alcohol use, unspecified with alcohol-induced mood disorder | | |
| F10950 | Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions | | |
| F10951 | Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations | | |
| F10959 | Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified | | |
| F1096 | Alcohol use, unspecified with alcohol-induced persisting amnestic disorder | | |
| F1097 | Alcohol use, unspecified with alcohol-induced persisting dementia | | |
| F10980 | Alcohol use, unspecified with alcohol-induced anxiety disorder | | |
| F10981 | Alcohol use, unspecified with alcohol-induced sexual dysfunction | | |
| F10982 | Alcohol use, unspecified with alcohol-induced sleep disorder | | |
| F10988 | Alcohol use, unspecified with other alcohol-induced disorder | | |
| F1099 | Alcohol use, unspecified with unspecified alcohol-induced disorder | | |
| F1120 | Opioid dependence, uncomplicated | | |
| F1121 | Opioid dependence, in remission | | |
| F1124 | Opioid dependence with opioid-induced mood disorder | | |
| F11250 | Opioid dependence with opioid-induced psychotic disorder with delusions | | |
| F11251 | Opioid dependence with opioid-induced psychotic disorder with hallucinations | | |
| F11259 | Opioid dependence with opioid-induced psychotic disorder, unspecified | | |
| F11281 | Opioid dependence with opioid-induced sexual dysfunction | | |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Opioid Dependency and Alcohol Abuse/Dependency Agents

| F11282 | Opioid dependence with opioid-induced sleep disorder |
|--------|--|
| F11288 | Opioid dependence with other opioid-induced disorder |
| F1129 | Opioid dependence with unspecified opioid-induced disorder |

Peptic Ulcer

Products DARTISLA (glycopyrrolate)

Claim 🗸

ICD-10 Description

Diagnosis Code Must Be Submitted on:

| .05 .0 | 200011011011 |
|--------|---|
| K270 | ACUTE PEPTIC ULCER, SITE UNSPECIFIED, WITH HEMORRHAGE |
| K271 | ACUTE PEPTIC ULCER, SITE UNSPECIFIED, WITH PERFORATION |
| K272 | ACUTE PEPTIC ULCER, SITE UNSPECIFIED, WITH BOTH HEMORRHAGE AND PERFORATION |
| K273 | ACUTE PEPTIC ULCER, SITE UNSPECIFIED, WITHOUT HEMORRHAGE OR PERFORATION |
| K274 | CHRONIC OR UNSPECIFIED PEPTIC ULCER, SITE UNSPECIFIED, WITH HEMORRHAGE |
| K275 | CHRONIC OR UNSPECIFIED PEPTIC ULCER, SITE UNSPECIFIED, WITH PERFORATION |
| K276 | CHRONIC OR UNSPECIFIED PEPTIC ULCER, SITE UNSPECIFIED, WITH BOTH HEMORRHAGE AND PER |
| K277 | CHRONIC PEPTIC ULCER, SITE UNSPECIFIED, WITHOUT HEMORRHAGE OR PERFORATION |
| K279 | PEPTIC ULCER, SITE UNSPECIFIED, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT HEMORRHAGE |
| | |

Prior Authorization Request

Progestational Agent

Products CRINONE 8% GEL (progesterone) Diagnosis Code Must Be Submitted on: Claim 🗸 Prior Authorization Request ICD-10 Description O09211 Supervision of pregnancy with history of pre-term labor, first trimester O09212 Supervision of pregnancy with history of pre-term labor, second trimester O09213 Supervision of pregnancy with history of pre-term labor, third trimester O09219 Supervision of pregnancy with history of pre-term labor, unspecified trimester Supervision of pregnancy with other poor reproductive or obstetric history, first trimester O09292 Supervision of pregnancy with other poor reproductive or obstetric history, second trimester O09293 Supervision of pregnancy with other poor reproductive or obstetric history, third trimester O09299 Supervision of pregnancy with other poor reproductive or obstetric history, unspecified trimester O26872 Cervical shortening, second trimester O26873 Cervical shortening, third trimester O26879 Cervical shortening, unspecified trimester

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Proteinuria Reduction

| D | rn | di | ıct | c |
|---|----|----|-----|---|

TARPEYO (budesonide dx effective 1/1/2022)

Diagnosis Code Must Be Submitted on: Claim ✓ Prior Authorization Request ✓

ICD-10 Description

N028 RECURRENT AND PERSISTENT HEMATURIA WITH OTHER MORPHOLOGIC CHANGES

Pulmonary Anti-Hypertensive Agents

Products

ADCIRCA (tadalafil)
REVATIO (sildenafil citrate)
ALYQ (tadalafil)
TADLIQ (tadalafil)

Diagnosis Code Must Be Submitted on: Claim ✓ Prior Authorization Request ✓

ICD-10 Description

| 1270 | Primary pulmonary hypertension |
|-------|---|
| 12720 | Pulmonary hypertension, unspecified |
| 12721 | Secondary pulmonary arterial hypertension |
| 12722 | Pulmonary hypertension due to left heart disease |
| 12723 | Pulmonary hypertension Due to Lung Diseases and hypoxia |
| 12724 | Chronic thromboembolic pulmonary hypertension |
| 12729 | Other secondary pulmonary hypertension |
| 12783 | Eisenmenger's syndrome |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Smoking Cessation

F902

F908

F909

Attention-deficit hyperactivity disorder, combined type

Attention-deficit hyperactivity disorder, unspecified type

Attention-deficit hyperactivity disorder, other type

Products bupropion hcl sr 150 mg tablet (Example brand: ZYBAN) CHANTIX (varenicline tartrate) nicotine gum (Example brand: NICORETTE) nicotine lozenge (Example brand: NICORETTE) nicotine lozenge (Example brand: NICOTINE) nicotine patch (Example brand: CVS NICOTINE) nicotine patch (Example brand: NICOTINE) NICOTROL (nicotine) NICOTROL NS (nicotine) Diagnosis Code Must Be Submitted on: Claim 🗸 Prior Authorization Request ICD-10 Description F17200 Nicotine dependence, unspecified, uncomplicated F17201 Nicotine dependence, unspecified, in remission F17203 Nicotine dependence unspecified, with withdrawal 17208 Nicotine dependence, unspecified, with other nicotine-induced disorders -17209 Nicotine dependence, unspecified, with unspecified nicotine-induced disorders F17210 Nicotine dependence, cigarettes, uncomplicated F17211 Nicotine dependence, cigarettes, in remission F17213 Nicotine dependence, cigarettes, with withdrawal F17218 Nicotine dependence, cigarettes, with other nicotine-induced disorders F17219 Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders F17220 Nicotine dependence, chewing tobacco, uncomplicated 17221 Nicotine dependence, chewing tobacco, in remission -17223 Nicotine dependence, chewing tobacco, with withdrawal 17228 Nicotine dependence, chewing tobacco, with other nicotine-induced disorders -17229 Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders 17290 Nicotine dependence, other tobacco product, uncomplicated F17291 Nicotine dependence, other tobacco product, in remission F17293 Nicotine dependence, other tobacco product, with withdrawal F17298 Nicotine dependence, other tobacco product, with other nicotine-induced disorders F17299 Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders Z720 Tobacco use Stimulants, Desoxyn **Products** DESOXYN (methamphetamine hcl) Diagnosis Code Must Be Submitted on: Claim 🗸 Prior Authorization Request **ICD-10** Description F900 Attention-deficit hyperactivity disorder, predominantly inattentive type F901 Attention-deficit hyperactivity disorder, predominantly hyperactive type

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Stimulants, Excluding Desoxyn and Vyvanse

Narcolepsy without cataplexy

G47419

| Produc | ts | | |
|---------|------------|---|---|
| ADDER | RALL (dext | troamphetamine/amphetamine) | ADDERALL XR (dextroamphetamine/amphetamine) |
| ADHAN | ISIA XR (r | methylphenidate) | ADZENYS XR-ODT (amphetamine) |
| APTEN | SIO XR (n | nethylphenidate hcl) | AZSTARYS (serdexmethylphenidate/dexmethylphenidat |
| CONCE | ERTA (met | thylphenidate hcl) | COTEMPLA XR-ODT (methylphenidate) |
| DAYTR | ANA (met | hylphenidate hcl) | DEXEDRINE (dextroamphetamine sulfate) |
| dextroa | mphetami | ne sulfate er (Example brand: DEXEDRINE) | DYANAVEL XR (amphetamine) |
| EVEKE | O (amphe | stamine) | FOCALIN (dexmethylphenidate hcl) |
| FOCAL | IN XR (de | xmethylphenidate hcl) | JORNAY PM (methylphenidate er) |
| METHY | LIN (meth | nylphenidate hcl) | methylphenidate er (Example brand: METADATE ER) |
| methylp | henidate (| er (Example brand: METHYLIN) | methylphenidate hcl (Example brand: METHYLIN CHEV |
| methylp | henidate l | hcl cd (Example brand: METADATE CD) | methylphenidate hcl er (cd) (Example brand: METADAT |
| | | la (Example brand: RITALIN LA) | MYDAYIS (dextroamphetamine/amphetamine) |
| PROCE | ENTRA (de | extroamphetamine sulfate) | QUILLIVANT XR (methylphenidate hcl) |
| | | (Iphenidate) | RITALIN (methylphenidate hcl) |
| | ٠, ٠, | hylphenidate hcl) | ZENZEDI (dextroamphetamine sulfate) |
| | Diagnosis | s Code Must Be Submitted on: Claim 🗸 | Prior Authorization Request 🗸 |
| | • | | • · · · · · · · · · · · · · · · · · · · |
| | ICD-10 | Description | Alice in a Adamatic control of the control |
| | F900 | Attention-deficit hyperactivity disorder, predominan | |
| | F901 | Attention-deficit hyperactivity disorder, predominan | * |
| | F902 | Attention-deficit hyperactivity disorder, combined ty | pe |
| | F908 | Attention-deficit hyperactivity disorder, other type | h |
| | F909 | Attention-deficit hyperactivity disorder, unspecified | type |
| | G47411 | Narcolepsy with cataplexy | |
| | G47419 | Narcolepsy without cataplexy | |
| timul | ants, | Vyvanse | |
| Produc | ts | | |
| VYVAN | SE (lisdex | kamfetamine dimesylate) | VYVANSE CHEWABLE (lisdexamfetamine dimesylate) |
| | Diagnosis | s Code Must Be Submitted on: Claim 🗹 | Prior Authorization Request |
| | ICD-10 | Description | |
| | F5081 | Binge Eating Disorder | |
| | F900 | Attention-deficit hyperactivity disorder, predominan | tly inattentive type |
| | F901 | Attention-deficit hyperactivity disorder, predominan | |
| | F902 | Attention-deficit hyperactivity disorder, combined ty | |
| | F908 | Attention-deficit hyperactivity disorder, other type | · |
| | F909 | Attention-deficit hyperactivity disorder, unspecified | type |
| | G47411 | Narcolepsy with cataplexy | 71 |
| | | | |

Diagnosis Restricted Drugs

Revised (page 12): 3/14/2023

Effective: 1/1/2023

Vitamins, Renal

Products

DIALYVITE (folic acid combination)

DIALYVITE 800 WITH IRON (fe fumarate combinations)

FOLBEE PLUS (folic acid combination)

HEMATINIC PLUS (iron combinations)

RENAL CAPS (vitamin b complex)

TRIPHROCAPS (vitamin b complex)

VP-VITE RX (vitamin b complex)

DIALYVITE 3000 (folic acid combination)
FERROCITE PLUS (iron combinations)
FOLBEE PLUS CZ (folic acid combination)
NEPHRO-VITE RX (vitamin b complex)
RENA-VITE RX (vitamin b complex)
VIRT-CAPS (vitamin b complex)

WESCAPS (vitamin b complex)

Diagnosis Code Must Be Submitted on: Claim ✓ Prior Authorization Request ☐

ICD-10 Description

| ICD-10 | Description |
|--------|--|
| N181 | Chronic kidney disease, Stage 1 |
| N182 | Chronic kidney disease, Stage 2 (mild) |
| N1830 | Chronic kidney disease, stage 3 unspecified |
| N1831 | Chronic kidney disease, stage 3A |
| N1832 | Chronic kidney disease, stage 3B |
| N184 | Chronic kidney disease, Stage 4 (severe) |
| N185 | Chronic kidney disease, Stage 5 |
| N186 | End stage renal disease |
| N189 | Chronic kidney disease, unspecified |
| N250 | Renal osteodystrophy |
| N251 | Nephrogenic diabetes insipidus |
| N2581 | Secondary hyperparathyroidism of renal origin |
| N2589 | Other disorders resulting from impaired renal tubular function |
| N259 | Disorder resulting from impaired renal tubular function, unspecified |
| | |